Daratumumab for delayed RBC engraftment following major ABO mismatched haploidentical bone marrow transplantation

• Published in: Transfusion (Philadelphia, Pa.) Pa.), 2021-04, Vol.61 (4), p.1041-1046
• Main Authors: Yates, Bonnie, Molloy, Eoghan, Dulau‐Florea, Alina, Braylan, Raul, Hogan, Laura, Hickstein, Dennis D., Freeman, Alexandra F., Kalsi, Shelley S., Shah, Nirali N.
• Format: Article
• Language: English
• Subjects: ABO system; Anemia; Aplasia; Bone marrow; Bone marrow transplantation; Case reports; CD38 antigen; Chimerism; Erythrocytes; Hemagglutinins; Hematopoietic stem cells; Hemoglobin; Immunodeficiency; Immunosuppression; Immunotherapy; Literature reviews; Monoclonal antibodies; Plasma cells; Primary immunodeficiencies; Stem cell transplantation; Stem cells; Transfusion; Transplantation; Transplants & implants
• ISSN: 0041-1132; 1537-2995
• DOI: 10.1111/trf.16281

Background Recent case reports have described the efficacy of daratumumab to treat refractory pure red cell aplasia (PRCA) following major ABO mismatched allogeneic hematopoietic stem cell transplantation (HSCT). In this report, we describe the use of daratumumab as a first‐line agent for treatment of delayed red blood cell (RBC) engraftment following a major ABO mismatched pediatric HSCT and provide a review of the literature. Study Design and Materials We report on a 14‐year‐old with DOCK8 deficiency who underwent a myeloablative, haploidentical bone marrow transplant from her major ABO mismatched sister (recipient O+, donor A+) for treatment of her primary immunodeficiency. Despite achieving full donor chimerism, she had delayed RBC engraftment requiring ongoing transfusions. Due to iron deposition, symptomatic anemia, and persistence of anti‐A iso‐hemagglutinins despite discontinuation of immunosuppression, treatment for delayed RBC engraftment with the CD38‐targeted monoclonal antibody daratumumab was selected as a less immunosuppressive agent that could more selectively target iso‐hemagglutinin producing plasma cells without causing broad B‐cell aplasia. Results Clinical effect with daratumumab was demonstrated by reduced iso‐hemagglutinin titer, increased reticulocytosis, normalization of her hemoglobin, and transfusion independence. In the 11‐month follow‐up period to date, no additional transfusions or immunosuppression have been necessary, despite persistence of low‐level anti‐A iso‐hemagglutinin. Conclusion Our experience suggests that daratumumab was an effective first‐line therapy for delayed RBC engraftment and that earlier consideration for daratumumab in treatment of delayed RBC engraftment may be warranted.